Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
10.1016/j.pnpbp.2015.07.001 2 AlfeiS.SchitoG
Oxidative stress in multiple sclerosis: central and peripheral mode of action
AXL in cancer: a modulator of drug resistance and therapeutic target
95% CI 0.35-0.53) 53,446 patients who received exenatide and other noninsulin therapies were 31% less likely to develop heart failure compared to those that took a noninsulin therapy and no exenatide (OR 0.69
Presented for research literature review only Hennessy S et al
US$ 23.43
US$ 26.91
US$ 21.21
US$ 25.69
US$ 24.43
US$ 28.94
